Luyang Li

Luyang Li

Auto-generated profile, based on publicly available information

Luyang Li

Postgraduate Training Base of Air Force Medical Center, China Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLuyang Li
Luyang Li
CLChengli Liu
Chengli Liu
TXTian Xia
Tian Xia
HLHaoming Li
Haoming Li
JYJun Yang
Jun Yang
TZTao Zhang
Tao Zhang
Background: The relationship between plant-based diets and gallstone disease has been debated. This study aimed to shed light on the association between plant-based dietary index and the risk of developing gallstone disease. Methods: Eligible participants were selected from National Health and Nutrition Examination Survey (NHANES) 2017–2020. Three plant-based diet indexes (PDI, healthy PDI, unhealthy PDI) were calculated using data from two NHANES 24-h dietary recall interviews. Restricted Cubic Spline and multivariate logistic regression were used to analyze the associations. Subgroup analysis was adopted to make the results more robust. Results: A total of 5673 eligible participants were analyzed. After adjusting for various confounding variables, uPDI was positively associated with gallstone disease (OR = 1.53, 95%CI: 1.02–2.29). No association was found between PDI/hPDI and gallstone disease (p > 0.05). The results of subgroup analysis did not show any positive association between uPDI and gallstones in specific groups. Conclusion: Our study shows that the elevated uPDI are linked to a higher risk of gallstone disease.

25 July 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
SZShuhan Zhang
Shuhan Zhang
LLLuyang Li
Luyang Li
CLChengli Liu
Chengli Liu
MPMeng Pu
Meng Pu
YMYingbo Ma
Yingbo Ma
TXTian Xia
Tian Xia
Background: Currently, there is a lack of effective indicators for predicting the efficacy of immunotherapy in patients with advanced hepatocellular carcinoma (HCC). This study aimed to investigate the expression and prognostic value of peripheral T lymphocyte subsets in advanced HCC. Methods: Patients with advanced HCC who were treated with immune checkpoint inhibitors (ICIs) from December 2021 to December 2023 were included in the study. Flow cytometry was used to detect lymphocyte subsets before treatment. The patients were divided into disease control (DC) and nondisease control (nDC) groups based on treatment efficacy. Relationships between the clinical characteristics/peripheral T lymphocytes and immunotherapy efficacy were analyzed. The effectiveness of peripheral T lymphocyte subsets in predicting immunotherapy efficacy for patients with advanced HCC was analyzed using receiver operating characteristic (ROC) curves. Results: A total of 40 eligible patients were included in this study. Non-DC was significantly associated with higher albumin-bilirubin (ALBI) scores. The percentages of γδ+Vδ2+PD1+ T cells and γδ+Vδ2+Tim3+ T cells were greater in the nDC group than in the DC group. Multivariable regression analysis revealed that the ALBI score and T lymphocytes expressing γδ+Vδ2+PD1+ and γδ+Vδ2+Tim3+ were founded to be independent influencing factors. The area under the ROC curve (AUC) values for these combinations was 0.944 (95% CI, 0.882 ~ 1.000). Conclusions: The calculation of the ALBI score and determination of the percentages CD3+γδ+Vδ2+PD1+ T lymphocytes and CD3+γδ+Vδ2+Tim3+ T lymphocytes in the peripheral blood of patients with advanced HCC are helpful for predicting the patients’ responses to ICIs, helping to screen patients who may clinically benefit from immunotherapy. Retrospectively registered: number: ChiCTR2400080409, date of registration: 2024-01-29.

10 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LLLuyang Li
Luyang Li
YWYongshuai Wang
Yongshuai Wang
FZFeng Zhang
Feng Zhang
YGYixiang Gan
Yixiang Gan
YZYitong Zhu
Yitong Zhu
LLLianxin Liu
Lianxin Liu
Background: Postoperative adjuvant therapy has yielded inconsistent benefits for patients with hepatocellular carcinoma (HCC) considered at high risk of recurrence after resection. This may partly reflect the limited ability of conventional clinicopathological criteria to capture the multi-dimensional heterogeneity underlying postoperative recurrence and precisely identify patients at genuinely high risk. We aimed to develop and externally validate an artificial intelligence (AI)-enabled multimodal framework to characterize postoperative recurrence heterogeneity and refine risk stratification after HCC resection.Methods: This multicenter retrospective study included 556 patients across development, external validation, exploratory adjuvant therapy cohorts and selected TCGA cohort. Clinical variables, MRI-derived radiomic features, and AI-derived histopathological representations were integrated for recurrence risk stratification. Histopathological interpretation, bulk transcriptomics, and single-cell RNA sequencing were used to characterize high-risk recurrence. Results: The multimodal framework achieved a C-index of 0.844 (95%CI, 0.772-0.905) in the development cohort and 0.774 (0.664-0.867), 0.818 (0.736-0.886) across external cohorts. Multimodal stratification further resolved recurrence heterogeneity within conventional risk groups: conventionally low-risk patients reclassified as multimodal high risk had increased recurrence risk (HR, 8.76; 95% CI, 4.12-18.60), whereas conventionally high-risk patients reclassified as multimodal low risk had reduced risk (HR, 0.15; 95% CI, 0.10-0.22). High-risk recurrence phenotyping was associated with invasive histopathological features, dysfunctional CD8+ T-cell states, and tumor-associated macrophage programs.Interpretation: AI-enabled multimodal phenotyping identifies clinically and biologically distinct postoperative recurrence-risk states beyond conventional clinicopathological stratification. This approach may provide a biologically informed framework for postoperative risk assessment and support more refined risk enrichment and patient stratification in future adjuvant clinical trials.